Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:6658 |
| Name | pulmonary large cell neuroendocrine carcinoma |
| Definition | |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:5721 |
| Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer lung carcinoma lung non-small cell carcinoma lung large cell carcinoma pulmonary large cell neuroendocrine carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
| NCT02687958 | Phase II | Everolimus | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | Unknown status | ITA | 0 |
| NCT05470595 | Phase II | Atezolizumab | A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung (LCNEC-ALPINE) | Active, not recruiting | DEU | 0 |
| NCT06613009 | Phase I | IBI3009 | Study of IBI3009 in Subjects With Unresectable, Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | Recruiting | AUS | 1 |
| NCT06814496 | Phase Ib/II | Tarlatamab | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) | Recruiting | USA | 0 |
| NCT06937905 | Phase III | Tarlatamab | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (TARLANEC) | Not yet recruiting | FRA | 0 |
| NCT07006727 | Phase I | 225Ac-ETN029 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | Recruiting | USA | CAN | 1 |